Literature DB >> 3970810

Combined modality management of local and disseminated adult soft tissue sarcomas: a review of 257 cases seen over 10 years at the Christie Hospital & Holt Radium Institute, Manchester.

V H Bramwell, D Crowther, D P Deakin, R Swindell, M Harris.   

Abstract

Over a 10 year period, between 1974-1984, 257 adult cases of tissue sarcoma have been evaluated in the Department of Medical Oncology, Christie Hospital, Manchester. At registration locally advanced or metastatic diseases was present in 162 (63%). The male/female ratio was 1.5:1 and median age 54 years (range 14-85). The commonest sites were lower limb (33%), visceral (21%), trunk (13%), retroperitoneum (12%) and upper limb (10%). Leiomyosarcoma (27%), liposarcoma (14%) malignant fibrous histiocytoma (10%) and neuro plus fibrosarcomas (15%) were the most frequent histological subtypes. A high proportion of uterine sarcomas (17%) is a point of distinction from many other series. Histological grade was specified in 72% of cases and the distribution (Grade I--27%; II--6%; III--67%) reflected a referral bias towards advanced disease. Local resection of the primary tumour was performed in 76% of cases. In many instances this only amounted to 'shelling out' and true compartmental excisions were rare. Amputation was performed in 31% of patients with limb sarcomas. Ninety-eight patients (38%) had experienced one or more local recurrences prior to referral and the overall local recurrence rate was 56%. Suitable patients (78%) received chemotherapy, 50% entering multicentre trials in collaboration with the EORTC. The commonest regime used in patients with advanced disease was CYVADIC which produced an overall response rate of 37%. Ifosfamide, used as a single agent in 16 patients, induced 3CR and 5PR for an overall response rate of 50%. When used in combination with MTX and VADIC, there was no difference in response rate, but numbers in these pilot studies were small. Seventeen high risk patients received adjuvant chemotherapy with VAC, but the results (11 relapses) were disappointing. An EORTC trial, comparing adjuvant CYVADIC chemotherapy with control has accrued 307 patients, 49 of these from the Christie Hospital. Preliminary results within this centre - 13/25 relapses in the control arm, 5/23 in the chemotherapy arm-suggest an advantage for chemotherapy but the data are statistically not significant. Post-operative radical radiotherapy after resection of the primary tumour or local recurrence was performed in 51 patients, with local control in 65% of cases, although metastases developed in 41%. At the time of analysis (1st April 1984) 98 (38%) were alive, of whom 72 showed no evidence of disease and 52 had never relapsed. Malignant disease was the cause of death in 92%. Overall survival was not influenced by sex, but patients less than 40 years of age fared significantly better (P less than 0.001).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1985        PMID: 3970810      PMCID: PMC1976948          DOI: 10.1038/bjc.1985.43

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  39 in total

1.  Malignant fibrous histiocytoma: an analysis of 200 cases.

Authors:  S W Weiss; F M Enzinger
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

2.  A clinical and pathological staging system for soft tissue sarcomas.

Authors:  W O Russell; J Cohen; F Enzinger; S I Hajdu; H Heise; R G Martin; W Meissner; W T Miller; R L Schmitz; H D Suit
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

3.  Evaluation of adjuvant therapy in soft tissue sarcoma. A collaborative multidisciplinary approach. E.O.R.T.C. protocol 62771.

Authors:  H M Pinedo; C P Vendrik; V H Bramwell; E A van Slooten; D P Deakin; J A van Unnik; M Staquet; R Sylvester; G Bonadonna
Journal:  Eur J Cancer       Date:  1979-05       Impact factor: 9.162

4.  Uterine sarcomas: analysis of failures with special emphasis on the use of adjuvant radiation therapy.

Authors:  O M Salazar; T A Bonfiglio; S F Patten; B E Keller; M L Feldstein; M E Dunne; J H Rudolph
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

5.  Uterine sarcomas: natural history, treatment and prognosis.

Authors:  O M Salazar; T A Bonfiglio; S F Patten; B E Keller; M Feldstein; M E Dunne; J Rudolph
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

6.  Malignant fibrous histiocytoma: a retrospective study of 167 cases.

Authors:  M M Kearney; E H Soule; J C Ivins
Journal:  Cancer       Date:  1980-01-01       Impact factor: 6.860

7.  Surgical treatment of 297 soft tissue sarcomas of the lower extremity.

Authors:  M H Shiu; E B Castro; S I Hajdu; J G Fortner
Journal:  Ann Surg       Date:  1975-11       Impact factor: 12.969

8.  Radiation therapy of soft tissue sarcomas.

Authors:  H D Suit; W O Russell
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

9.  A reassessment of uterine neoplasms originally diagnosed as leiomyosarcomas.

Authors:  W R Hart; J K Billman
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

10.  Increased incidence of brain metastases in sarcoma patients.

Authors:  P España; P Chang; P H Wiernik
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

View more
  8 in total

1.  An effective chemotherapy regimen for liver metastasis from retroperitoneal fibrosarcoma: report of a case.

Authors:  H Isobe; Y Wada; J Ryo; T Matsushita; T Makino; B Satoh; S Kanaya; T Katayama; M Ohtoshi
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

2.  Soft tissue sarcomas of the extremities and trunk in the adult. Report of 124 cases.

Authors:  C Zornig; H J Weh; A Krüll; R Schwarz; R E Hilgert; S Schröder
Journal:  Langenbecks Arch Chir       Date:  1992

3.  Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.

Authors:  V H Bramwell; H T Mouridsen; A Santoro; G Blackledge; R Somers; D Thomas; R Sylvester; A Van Oosterom
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum.

Authors:  D P Jaques; D G Coit; S I Hajdu; M F Brennan
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

5.  The diagnosis of soft tissue tumours.

Authors:  J W Serpell; S H Fish; C Fisher; J M Thomas
Journal:  Ann R Coll Surg Engl       Date:  1992-07       Impact factor: 1.891

6.  A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.

Authors:  B M Cantwell; J Carmichael; S Ghani; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Prognostic factors for survival in soft tissue sarcoma.

Authors:  J N el-Jabbour; S S Akhtar; G R Kerr; K M McLaren; J F Smyth; A Rodger; R C Leonard
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

8.  Sarcomas in north west England: III. Survival.

Authors:  A L Hartley; V Blair; M Harris; J M Birch; S S Banerjee; A J Freemont; J McClure; L J McWilliam
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.